JP2017523784A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017523784A5 JP2017523784A5 JP2017505792A JP2017505792A JP2017523784A5 JP 2017523784 A5 JP2017523784 A5 JP 2017523784A5 JP 2017505792 A JP2017505792 A JP 2017505792A JP 2017505792 A JP2017505792 A JP 2017505792A JP 2017523784 A5 JP2017523784 A5 JP 2017523784A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- sequence shown
- amino acid
- acid sequence
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 134
- 108091008874 T cell receptors Proteins 0.000 claims description 97
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 97
- 210000004027 cell Anatomy 0.000 claims description 91
- 102000014914 Carrier Proteins Human genes 0.000 claims description 73
- 108091008324 binding proteins Proteins 0.000 claims description 73
- 108091033319 polynucleotide Proteins 0.000 claims description 72
- 239000002157 polynucleotide Substances 0.000 claims description 72
- 102000040430 polynucleotide Human genes 0.000 claims description 72
- 239000002773 nucleotide Substances 0.000 claims description 58
- 125000003729 nucleotide group Chemical group 0.000 claims description 58
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 32
- 206010028980 Neoplasm Diseases 0.000 claims description 25
- 108010081208 RMFPNAPYL Proteins 0.000 claims description 17
- 201000011510 cancer Diseases 0.000 claims description 15
- 239000013604 expression vector Substances 0.000 claims description 13
- 239000000427 antigen Substances 0.000 claims description 12
- 102000036639 antigens Human genes 0.000 claims description 12
- 108091007433 antigens Proteins 0.000 claims description 12
- 210000000987 immune system Anatomy 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
- 208000035475 disorder Diseases 0.000 claims description 11
- 230000003463 hyperproliferative effect Effects 0.000 claims description 11
- 206010009944 Colon cancer Diseases 0.000 claims description 10
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims description 10
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 10
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 10
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 10
- 208000021668 chronic eosinophilic leukemia Diseases 0.000 claims description 10
- 210000003071 memory t lymphocyte Anatomy 0.000 claims description 10
- 239000007787 solid Substances 0.000 claims description 10
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 8
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 8
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 claims description 8
- 108010075704 HLA-A Antigens Proteins 0.000 claims description 8
- 239000012634 fragment Substances 0.000 claims description 8
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 7
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 5
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 5
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 5
- 206010005003 Bladder cancer Diseases 0.000 claims description 5
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 5
- 206010006187 Breast cancer Diseases 0.000 claims description 5
- 208000026310 Breast neoplasm Diseases 0.000 claims description 5
- 201000009030 Carcinoma Diseases 0.000 claims description 5
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 5
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 5
- 206010052360 Colorectal adenocarcinoma Diseases 0.000 claims description 5
- 206010014733 Endometrial cancer Diseases 0.000 claims description 5
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 5
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 5
- 208000009849 Female Genital Neoplasms Diseases 0.000 claims description 5
- 201000010915 Glioblastoma multiforme Diseases 0.000 claims description 5
- 206010066476 Haematological malignancy Diseases 0.000 claims description 5
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 5
- 208000034578 Multiple myelomas Diseases 0.000 claims description 5
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 5
- 206010033128 Ovarian cancer Diseases 0.000 claims description 5
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 5
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 5
- 206010060862 Prostate cancer Diseases 0.000 claims description 5
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 5
- 206010038389 Renal cancer Diseases 0.000 claims description 5
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 5
- 206010039491 Sarcoma Diseases 0.000 claims description 5
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 5
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims description 5
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims description 5
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 5
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 5
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 5
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 5
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 5
- 210000001130 astrocyte Anatomy 0.000 claims description 5
- 201000009036 biliary tract cancer Diseases 0.000 claims description 5
- 208000020790 biliary tract neoplasm Diseases 0.000 claims description 5
- 210000000988 bone and bone Anatomy 0.000 claims description 5
- 201000010881 cervical cancer Diseases 0.000 claims description 5
- 208000029742 colonic neoplasm Diseases 0.000 claims description 5
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims description 5
- 210000004443 dendritic cell Anatomy 0.000 claims description 5
- 239000012636 effector Substances 0.000 claims description 5
- 201000004101 esophageal cancer Diseases 0.000 claims description 5
- 201000006585 gastric adenocarcinoma Diseases 0.000 claims description 5
- 206010017758 gastric cancer Diseases 0.000 claims description 5
- 210000004602 germ cell Anatomy 0.000 claims description 5
- 208000005017 glioblastoma Diseases 0.000 claims description 5
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims description 5
- 201000010985 invasive ductal carcinoma Diseases 0.000 claims description 5
- 201000010982 kidney cancer Diseases 0.000 claims description 5
- 201000007270 liver cancer Diseases 0.000 claims description 5
- 208000014018 liver neoplasm Diseases 0.000 claims description 5
- 201000005202 lung cancer Diseases 0.000 claims description 5
- 208000020816 lung neoplasm Diseases 0.000 claims description 5
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 5
- 201000001441 melanoma Diseases 0.000 claims description 5
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 5
- 210000000822 natural killer cell Anatomy 0.000 claims description 5
- 201000008968 osteosarcoma Diseases 0.000 claims description 5
- 201000002528 pancreatic cancer Diseases 0.000 claims description 5
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 5
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims description 5
- 201000000849 skin cancer Diseases 0.000 claims description 5
- 210000004872 soft tissue Anatomy 0.000 claims description 5
- 201000011549 stomach cancer Diseases 0.000 claims description 5
- 230000002381 testicular Effects 0.000 claims description 5
- 201000002510 thyroid cancer Diseases 0.000 claims description 5
- 206010044412 transitional cell carcinoma Diseases 0.000 claims description 5
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 5
- 206010046766 uterine cancer Diseases 0.000 claims description 5
- 208000037965 uterine sarcoma Diseases 0.000 claims description 5
- 239000013598 vector Substances 0.000 claims description 5
- 230000014509 gene expression Effects 0.000 claims description 4
- 230000035772 mutation Effects 0.000 claims description 4
- 108020004705 Codon Proteins 0.000 claims description 3
- 239000013603 viral vector Substances 0.000 claims description 3
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims description 2
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 230000037430 deletion Effects 0.000 claims description 2
- 238000012217 deletion Methods 0.000 claims description 2
- 210000000265 leukocyte Anatomy 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims description 2
- 210000003515 double negative t cell Anatomy 0.000 claims 1
- 230000003394 haemopoietic effect Effects 0.000 claims 1
- 108020001580 protein domains Proteins 0.000 claims 1
- 230000001177 retroviral effect Effects 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
- 238000000034 method Methods 0.000 description 31
- 108090000695 Cytokines Proteins 0.000 description 6
- 102000004127 Cytokines Human genes 0.000 description 6
- 102100022748 Wilms tumor protein Human genes 0.000 description 4
- 230000001400 myeloablative effect Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 108010002350 Interleukin-2 Proteins 0.000 description 3
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 230000005867 T cell response Effects 0.000 description 2
- 230000030741 antigen processing and presentation Effects 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 101000621309 Homo sapiens Wilms tumor protein Proteins 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 229940046731 calcineurin inhibitors Drugs 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
- 231100000782 microtubule inhibitor Toxicity 0.000 description 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
- 229960000951 mycophenolic acid Drugs 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462033045P | 2014-08-04 | 2014-08-04 | |
| US62/033,045 | 2014-08-04 | ||
| US201562164783P | 2015-05-21 | 2015-05-21 | |
| US62/164,783 | 2015-05-21 | ||
| PCT/US2015/042986 WO2016022400A1 (en) | 2014-08-04 | 2015-07-30 | T cell immunotherapy specific for wt-1 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018142600A Division JP2018183175A (ja) | 2014-08-04 | 2018-07-30 | Ｗｔ−１に特異的なｔ細胞免疫治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017523784A JP2017523784A (ja) | 2017-08-24 |
| JP2017523784A5 true JP2017523784A5 (cg-RX-API-DMAC7.html) | 2018-09-06 |
| JP6712261B2 JP6712261B2 (ja) | 2020-06-24 |
Family
ID=53901124
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017505792A Active JP6712261B2 (ja) | 2014-08-04 | 2015-07-30 | Ｗｔ−１に特異的なｔ細胞免疫治療 |
| JP2018142600A Pending JP2018183175A (ja) | 2014-08-04 | 2018-07-30 | Ｗｔ−１に特異的なｔ細胞免疫治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018142600A Pending JP2018183175A (ja) | 2014-08-04 | 2018-07-30 | Ｗｔ−１に特異的なｔ細胞免疫治療 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US10538572B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3177314B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP6712261B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN107074970B (cg-RX-API-DMAC7.html) |
| CA (1) | CA2956545A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2841274T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2016022400A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112016011567A2 (pt) | 2013-11-22 | 2017-10-24 | Hutchinson Fred Cancer Res | receptores de célula t humana de alta afinidade geneticamente modificados. |
| ES2979088T3 (es) | 2015-03-05 | 2024-09-24 | Fred Hutchinson Cancer Center | Proteínas de fusión inmunomoduladoras y usos de las mismas |
| US10975436B2 (en) | 2016-01-05 | 2021-04-13 | Diamir, Llc | Methods of using miRNA from bodily fluids for diagnosis and monitoring of neurodevelopmental disorders |
| JP7254519B2 (ja) | 2016-04-08 | 2023-04-10 | イムノコア リミテッド | Ｔ細胞レセプター |
| US10188749B2 (en) | 2016-04-14 | 2019-01-29 | Fred Hutchinson Cancer Research Center | Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers |
| US11261428B2 (en) | 2018-03-15 | 2022-03-01 | KSQ Therapeutics, Inc. | Gene-regulating compositions and methods for improved immunotherapy |
| US11332713B2 (en) | 2016-11-16 | 2022-05-17 | KSQ Therapeutics, Inc. | Gene-regulating compositions and methods for improved immunotherapy |
| IL266892B2 (en) | 2016-12-02 | 2025-10-01 | Univ Southern California | Artificial immune receptors and methods of using them |
| CN110121336A (zh) | 2017-01-05 | 2019-08-13 | 弗莱德哈钦森癌症研究中心 | 改善疫苗功效的系统和方法 |
| JP7131775B2 (ja) * | 2017-02-06 | 2022-09-06 | 国立研究開発法人国立がん研究センター | 新規ｔ細胞受容体 |
| SG11201908527SA (en) * | 2017-03-15 | 2019-10-30 | Hutchinson Fred Cancer Res | High affinity mage-a1-specific tcrs and uses thereof |
| JP2020511136A (ja) | 2017-03-17 | 2020-04-16 | フレッド ハッチンソン キャンサー リサーチ センター | 免疫調節性融合タンパク質およびその使用 |
| TWI835730B (zh) | 2017-04-24 | 2024-03-21 | 義大利聖拉斐爾醫院 | Ｔｃｒ及肽 |
| NL2019156B1 (en) * | 2017-06-30 | 2019-01-10 | Academisch Ziekenhuis Leiden H O D N Leids Univ Medisch Centrum | Treatment of haematological malignancies |
| WO2019004831A1 (en) * | 2017-06-30 | 2019-01-03 | Academisch Ziekenhuis Leiden (H.O.D.N. Leids Universitair Medisch Centrum) | TREATMENT OF HEMATOLOGICAL MALIGNANCIES |
| CN107267463A (zh) * | 2017-08-23 | 2017-10-20 | 安徽惠恩生物科技股份有限公司 | 一种针对乳腺癌的Car‑NK细胞制备方法 |
| EP4170029A3 (en) | 2017-09-19 | 2023-08-30 | Tropic Biosciences UK Limited | Modifying the specifity of plant non-coding rna molecules for silencing gene expression |
| US11952408B2 (en) | 2017-10-03 | 2024-04-09 | Juno Therapeutics, Inc. | HPV-specific binding molecules |
| CN109777778B (zh) * | 2017-11-14 | 2023-07-18 | 中国科学院广州生物医药与健康研究院 | 一种基因改造的γδT细胞 |
| TWI805665B (zh) | 2017-12-21 | 2023-06-21 | 瑞士商赫孚孟拉羅股份公司 | 結合hla-a2/wt1之抗體 |
| US12280092B2 (en) | 2018-01-05 | 2025-04-22 | Nantbio, Inc. | Reprogrammed T cell-like NK cells |
| JP7558563B2 (ja) | 2018-03-15 | 2024-10-01 | ケーエスキュー セラピューティクス， インコーポレイテッド | 免疫療法の改善のための遺伝子調節組成物及び遺伝子調節方法 |
| DE102018108612A1 (de) | 2018-03-21 | 2019-09-26 | Immatics US, Inc. | Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen |
| US20210015869A1 (en) * | 2018-04-05 | 2021-01-21 | Juno Therapeutics, Inc. | T cells expressing a recombinant receptor, related polynucleotides and methods |
| RU2020135968A (ru) * | 2018-04-05 | 2022-05-06 | Джуно Терапьютикс, Инк. | T-клеточные рецепторы и модифицированные клетки, экспрессирующие |
| EP3806888B1 (en) | 2018-06-12 | 2024-01-31 | Obsidian Therapeutics, Inc. | Pde5 derived regulatory constructs and methods of use in immunotherapy |
| CN112585162B (zh) * | 2018-08-06 | 2025-01-28 | 基因医疗免疫疗法有限责任公司 | Ha-1特异性t细胞受体及其用途 |
| JP7558151B2 (ja) * | 2018-09-05 | 2024-09-30 | アダプティミューン・リミテッド | Ｔ細胞改変 |
| TWI851607B (zh) * | 2018-10-05 | 2024-08-11 | 日商癌免疫研究所股份有限公司 | 良性腫瘤之預防或治療藥 |
| CN113227374A (zh) | 2018-10-16 | 2021-08-06 | 因特利亚治疗公司 | 用于免疫疗法的组合物和方法 |
| GB201817821D0 (en) * | 2018-10-31 | 2018-12-19 | Ospedale San Raffaele Srl | TCR and peptides |
| CN113784978B (zh) | 2019-03-11 | 2025-07-25 | 弗雷德哈钦森癌症中心 | 高亲合力wt1 t细胞受体及其用途 |
| CN111714618B (zh) * | 2019-03-22 | 2024-07-12 | 香雪生命科学技术（广东）有限公司 | T细胞和高亲和力pd-1融合蛋白的组合 |
| EP3750547A1 (en) | 2019-06-13 | 2020-12-16 | Universitätsmedizin der Johannes Gutenberg-Universität Mainz | Modified nk-92 cells, and therapeutic and diagnostic uses thereof |
| JP7737978B2 (ja) * | 2019-08-20 | 2025-09-11 | フレッド ハッチンソン キャンサー センター | Ｗｔ－１に特異的なｔ細胞免疫療法 |
| EP4086281A4 (en) * | 2019-12-30 | 2024-02-14 | China Immunotech (Beijing) Biotechnology Co., Ltd | IMPROVED STAR T CELL RECEPTOR AND ITS APPLICATION |
| CN114106144B (zh) * | 2020-08-27 | 2024-01-26 | 溧阳瑅赛生物医药有限公司 | 识别hla-a*02/wt1靶点的tcr及其应用 |
| WO2022132836A2 (en) | 2020-12-14 | 2022-06-23 | Fred Hutchinson Cancer Research Center | Compositions and methods for cellular immunotherapy |
| CA3215997A1 (en) * | 2021-04-21 | 2022-10-27 | Connor SWEENEY | Method and composition |
| WO2022246250A1 (en) * | 2021-05-20 | 2022-11-24 | Washington University | Neuroprotective compositions and methods |
| EP4370541A1 (en) | 2021-07-14 | 2024-05-22 | 2seventy bio, Inc. | Engineered t cell receptors fused to binding domains from antibodies |
| CN113773378B (zh) * | 2021-10-14 | 2023-11-03 | 深圳大学总医院 | T细胞受体及其应用 |
| EP4423144A4 (en) * | 2021-10-29 | 2025-10-08 | Yafei Hou | T CELL RECEPTOR RECOGNIZING THE S37F MUTATION IN CTNNB1 AND ITS USE |
| WO2023196996A2 (en) | 2022-04-08 | 2023-10-12 | 2Seventy Bio, Inc. | Multipartite receptor and signaling complexes |
| EP4573117A1 (en) | 2022-08-18 | 2025-06-25 | Immunocore Ltd | T cell receptor fusion proteins specific for mage a4 |
| WO2024092265A2 (en) * | 2022-10-28 | 2024-05-02 | Memorial Sloan-Kettering Cancer Center | T cell receptors targeting ewsr1-wt1 fusion protein and uses thereof |
| WO2024178397A2 (en) | 2023-02-24 | 2024-08-29 | Elevatebio Technologies, Inc. | Modified immune effector cells and methods of use |
| AU2024310260A1 (en) | 2023-06-29 | 2025-12-11 | Dispatch Biotherapeutics, Inc. | Synthetic cytokine receptors |
| WO2025240518A1 (en) | 2024-05-14 | 2025-11-20 | Dispatch Biotherapeutics, Inc. | Modified lentiviral transfer plasmids |
| GB202406990D0 (en) * | 2024-05-16 | 2024-07-03 | Univ Oxford Innovation Ltd | T cell receptors and uses thereof |
| WO2025245169A1 (en) | 2024-05-21 | 2025-11-27 | Fred Hutchinson Cancer Center | Immunotherapy cells equipped with a collagen-targeting payload |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5283173A (en) | 1990-01-24 | 1994-02-01 | The Research Foundation Of State University Of New York | System to detect protein-protein interactions |
| US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
| GB9518220D0 (en) | 1995-09-06 | 1995-11-08 | Medical Res Council | Checkpoint gene |
| ATE420112T1 (de) | 1998-07-31 | 2009-01-15 | Int Inst Cancer Immunology Inc | Krebsantigene, basierend auf dem tumorunterdrückenden genprodukt wt1 |
| GB9823897D0 (en) | 1998-11-02 | 1998-12-30 | Imp College Innovations Ltd | Immunotherapeutic methods and molecules |
| AU2003262094A1 (en) | 2002-09-12 | 2004-04-30 | Haruo Sugiyama | Cancer antigen peptide preparation |
| US7575925B2 (en) | 2002-12-10 | 2009-08-18 | Sunnybrook Health Sciences Centre | Cell preparations comprising cells of the T cell lineage and methods of making and using them |
| DK1731605T3 (da) | 2004-03-31 | 2010-05-25 | Int Inst Cancer Immunology Inc | Cancerantigenpeptider der er afledt af WT1 |
| JP2008527001A (ja) | 2005-01-13 | 2008-07-24 | ザ ジョンズ ホプキンス ユニバーシティー | 前立腺幹細胞抗原ワクチンおよびその使用 |
| CN102272153B (zh) | 2008-11-24 | 2015-04-15 | 德国慕尼黑亥姆霍兹研究中心健康和环境有限公司 | 高亲和力t细胞受体及其应用 |
| EP2258719A1 (en) | 2009-05-19 | 2010-12-08 | Max-Delbrück-Centrum für Molekulare Medizin (MDC) | Multiple target T cell receptor |
| GB0911566D0 (en) * | 2009-07-03 | 2009-08-12 | Immunocore Ltd | T cell receptors |
| CA3071740C (en) | 2010-09-20 | 2020-09-08 | Biontech Ag | Antigen-specific t cell receptors and t cell epitopes |
| CN104395462B (zh) * | 2012-05-03 | 2017-09-26 | 弗雷德哈钦森癌症研究中心 | 增强亲和力的t细胞受体及其制备方法 |
| WO2014018863A1 (en) | 2012-07-27 | 2014-01-30 | The Board Of Trustees Of The University Of Illinois | Engineering t-cell receptors |
| CN105377886B (zh) * | 2013-01-29 | 2020-07-28 | 马克思-德布鲁克-分子医学中心（Mdc）柏林-布赫 | 识别mage-a1的高亲和力结合分子 |
-
2015
- 2015-07-30 JP JP2017505792A patent/JP6712261B2/ja active Active
- 2015-07-30 EP EP15753531.1A patent/EP3177314B1/en active Active
- 2015-07-30 WO PCT/US2015/042986 patent/WO2016022400A1/en not_active Ceased
- 2015-07-30 CN CN201580049647.6A patent/CN107074970B/zh active Active
- 2015-07-30 US US14/813,782 patent/US10538572B2/en active Active
- 2015-07-30 ES ES15753531T patent/ES2841274T3/es active Active
- 2015-07-30 CA CA2956545A patent/CA2956545A1/en active Pending
-
2018
- 2018-07-30 JP JP2018142600A patent/JP2018183175A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017523784A5 (cg-RX-API-DMAC7.html) | ||
| JP7157839B2 (ja) | 癌治療のための免疫療法とサイトカイン制御療法との組み合わせ | |
| JP7527049B2 (ja) | Ｃａｒ発現ベクター及びｃａｒ発現ｔ細胞 | |
| JP7223055B2 (ja) | 癌治療のための併用免疫療法及びサイトカイン制御療法 | |
| Di et al. | Combined adjuvant of poly I: C improves antitumor effects of CAR-T cells | |
| Dotti et al. | Design and development of therapies using chimeric antigen receptor‐expressing T cells | |
| Baxevanis et al. | Cancer immunotherapy | |
| JP2020509767A5 (cg-RX-API-DMAC7.html) | ||
| Kershaw et al. | Gene-engineered T cells for cancer therapy | |
| Helmy et al. | Cancer immunotherapy: accomplishments to date and future promise | |
| Redeker et al. | Improving adoptive T cell therapy: the particular role of T cell costimulation, cytokines, and post-transfer vaccination | |
| Geller et al. | Use of allogeneic NK cells for cancer immunotherapy | |
| Bernatchez et al. | Advances in the treatment of metastatic melanoma: adoptive T-cell therapy | |
| JP2016520074A5 (cg-RX-API-DMAC7.html) | ||
| JP2017531687A5 (cg-RX-API-DMAC7.html) | ||
| WO2017159736A1 (ja) | 免疫機能制御因子を発現する免疫担当細胞及び発現ベクター | |
| WO2018193119A1 (en) | Gene therapy | |
| JP2020533962A5 (cg-RX-API-DMAC7.html) | ||
| Dhodapkar et al. | Hematologic malignancies: plasma cell disorders | |
| Reynders et al. | Radiotherapy and immunotherapy: improving cancer treatment through synergy | |
| Brayer et al. | Developing strategies in the immunotherapy of leukemias | |
| Garber et al. | Adoptive T-cell therapy for Leukemia | |
| Hanagiri et al. | Retracted: Antitumor activity of human γδ T cells transducted with CD 8 and with T‐cell receptors of tumor‐specific cytotoxic T lymphocytes | |
| Croce et al. | New immunotherapeutic strategies for the treatment of neuroblastoma | |
| Dellabona et al. | On the use of donor-derived iNKT cells for adoptive immunotherapy to prevent leukemia recurrence in pediatric recipients of HLA haploidentical HSCT for hematological malignancies |